Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Score
Capricor Therapeutics, Inc. price target
| CAPR | |
|---|---|
| Low | $3.50 |
| Average | $12.70 |
| High | $25.00 |
| Upside vs current price | +33.3% |
The average target of $12.70 is +33.3% versus the current CAPR price of $9.53.
Capricor Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 3 |
| Hold | 6 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
10 analysts cover CAPR.
Capricor Therapeutics, Inc. EPS and revenue estimates
CAPR shows the next fiscal years with at least three analysts: 2026 EPS $-1.54, 2027 EPS $-1.49. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.54 | $92.18M |
| 2027 | $-1.49 | $83.76M |
Is Capricor Therapeutics, Inc. a buy or sell?
Of the 10 analysts covering Capricor Therapeutics, Inc., 4 rate it a buy (1 strong buy and 3 buy), 6 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The CAPR consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.
The average target of $12.70 implies +33.3% versus the current price of $9.53.
Those 10 ratings on CAPR are a headcount, and the label on file is Buy.
Reading the Capricor Therapeutics, Inc. forecast
The CAPR target range is wide: $3.50 at the low end, $12.70 in the middle, and $25.00 at the top.
Set next to the $9.53 CAPR quote, that average is +33.3%.
The CAPR ratings are split: 4 of 10 analysts are on the buy side, 6 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Recent CAPR revisions are two-sided: 3 upgrades and 4 downgrades.
The CAPR EPS path from 2026 ($-1.54) to 2027 ($-1.49) is rising.
Only 10 analysts cover CAPR, so the average rests on a short list.
Capricor Therapeutics, Inc. forecast questions
What is the CAPR price target?
The published range for CAPR is $3.50 to $25.00, with an average of $12.70. That average is +33.3% versus the current price of $9.53.
Is Capricor Therapeutics, Inc. a buy or sell?
Of the 10 analysts covering Capricor Therapeutics, Inc., 4 rate it a buy, 6 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the CAPR headcount is 4 buy, 6 hold, and 0 sell.
What is the EPS estimate for Capricor Therapeutics, Inc.?
Analyst EPS estimates for Capricor Therapeutics, Inc.: 2026 $-1.54, 2027 $-1.49.
What is the revenue estimate for Capricor Therapeutics, Inc.?
Analyst revenue estimates for Capricor Therapeutics, Inc.: 2026 $92.18M, 2027 $83.76M.
How many analysts cover CAPR?
10 analysts cover CAPR. Their consensus on CAPR is Buy, across those 10.